Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854 | EBOVAC1 | Project | Results | H2020 | CORDIS

Resultado final

Scientific publications

Migration

Publish Information Governance Policy

Migration

Communication tools: project website, flyer, information sheets for different audiences

Migration

Publicaciones

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses

Autores: Helen R. Wagstaffe, Elizabeth A. Clutterbuck, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Matthew D. Snape, Andrew J. Pollard, Eleanor M. Riley, and Martin R. Goodier.
Publicado en: The Journal of Clinical Investigation, Edición 130(7), 2020, Página(s) 3936-3946, ISSN 0021-9738
Editor: American Society for Clinical Investigation
DOI: 10.1172/jci132438

An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.

Autores: Steven E. Bellan, Rosalind M. Eggo, Pierre-Stéphane Gsell, Adam J. Kucharski, Natalie E. Dean, Richard Donohue, Matt Zook, W. John Edmunds, Frank Odhiambo, Ira M. Longini, Marc Brisson, Barbara E. Mahon, Ana Maria Henao-Restrepo.
Publicado en: Vaccine, Edición 37, 2019, Página(s) 4376-4381, ISSN 0264-410X
Editor: Elsevier BV
DOI: 10.1016/j.vaccine.2019.06.019

Assessing the performance of real-time epidemic forecasts: A case study of Ebola in the Western Area region of Sierra Leone, 2014-15

Autores: Sebastian Funk, Anton Camacho, Adam J. Kucharski, Rachel Lowe, Rosalind M. Eggo, W. John Edmunds
Publicado en: PLOS Computational Biology, Edición 15/2, 2019, Página(s) e1006785, ISSN 1553-7358
Editor: PLOS
DOI: 10.1371/journal.pcbi.1006785

Partnership for Research on Ebola Vaccination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.

Autores: Moses Badio, Edouard Lhomme, Mark Kieh, Abdoul Habib Beavogui, Stephen B. Kennedy, Seydou Doumbia, Bailah Leigh, Samba O. Sow, Alpha Diallo, Daniela Fusco, Matthew Kirchoff, Monique Termote, Renaud Vatrinet, Deborah Wentworth, Helène Esperou, H. Clifford Lane, Jerome Pierson, Deborah Watson-Jones, Céline Roy, Eric D’Ortenzio, Brian Greenwood, Genevieve Chêne, Laura Richert, James D. Neaton, Y
Publicado en: Trials, Edición 22, 2021, Página(s) 86, ISSN 1745-6215
Editor: BioMed Central
DOI: 10.1186/s13063-021-05035-9

A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus.

Autores: Irene Balelli, Chloé Pasin, Mélanie Prague, Fabien Crauste, Thierry Van Effelterre, Viki Bockstal, Laura Solforosi and Rodolphe Thiébaut.
Publicado en: Journal of Theoretical Biology, Edición 495 (2020), 2020, Página(s) 110254, ISSN 0022-5193
Editor: Academic Press
DOI: 10.1016/j.jtbi.2020.110254

Comparative ethnographies of medical research: materiality, social relations, citizenship and hope in Tanzania and Sierra Leone

Autores: Shelley Lees, Luisa Enria
Publicado en: International Health, Edición 12/6, 2020, Página(s) 575-583, ISSN 1876-3413
Editor: Elsevier BV
DOI: 10.1093/inthealth/ihaa071

Safety and immunogenicity of a two-dose Ad26. ZEBOV, MVA-BN-Filo Ebola vaccine in children: a randomised, double-blind, controlled trial in Sierra Leone.

Autores: Muhammed O. Afolabi, David Ishola, Daniela Manno, Babajide Keshinro,Viki Bockstal, Baimba Rogers, Kwabena Owusu-Kyei, Alimamy Serry-Bangura, Ibrahim Swaray, Brett Lowe, Dickens Kowuor, Frank Baiden, Thomas Mooney, Elizabeth Smout, Brian Köhn, Godfrey T. Otieno, Morrison Jusu, Julie Foster, Mohamed Samai, Gibrilla Fadlu Deen, Heidi Larson, Shelley Lees, Neil Goldstein, Katherine E. Gallagher, Aug
Publicado en: Lancet Infectious Diseases, Edición S1473-3099(21)00128-6, 2021, ISSN 1473-3099
Editor: The Lancet Publishing Group
DOI: 10.1016/s1473-3099(21)00128-6

Safety and long-term immunogenicity of a two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in adults: a randomised, double-blind, controlled trial in Sierra Leone.

Autores: David Ishola, Daniela Manno, Muhammed O. Afolabi, Babajide Keshinro, Viki Bockstal, Baimba Rogers, Kwabena Owusu-Kyei, Alimamy Serry-Bangura, Ibrahim Swaray, Brett Lowe, Dickens Kowuor, Frank Baiden, Thomas Mooney, Elizabeth Smout, Brian Köhn, Godfrey T. Otieno, Morrison Jusu, Julie Foster, Mohamed Samai, Gibrilla Fadlu Deen, Heidi Larson, Shelley Lees, Neil Goldstein, Katherine E. Gallagher, Aug
Publicado en: Lancet Infectious Diseases, Edición S1473-3099(21)00128-6, 2021, ISSN 1473-3099
Editor: The Lancet Publishing Group
DOI: 10.1016/s1473-3099(21)00125-0

Modelling results from The impact of control strategies and behavioural changes on the elimination of Ebola from Lofa County, Liberia

Autores: Funk, Sebastian; Iza Ciglenecki; Tiffany, Amanda; Gignoux, Etienne; Camacho, Anton; Eggo, Rosalind M.; Kucharski, Adam J.; W. John Edmunds; Bolongei, Josephus; Azuma, Phillip; Clement, Peter; Tamba, Alpha; Sterk, Esther; Telfer, Barbara; Engel, Gregory; Parker, Lucy Anne; Suzuki, Motoi; Heijenberg, Nico; Reeder, Bruce
Publicado en: Philosophical Transactions of the Royal Society, Edición 1, 2017, ISSN 0962-8436
Editor: Royal Society of London
DOI: 10.1098/rstb.2016.0302

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

Autores: Jonathan Kitonsa, Abu-Baker Ggayi, Zacchaeus Anywaine, Eva Kisaakye, Laura Nsangi, Vincent Basajja, Mary Nyantaro, Deborah Watson-Jones, Georgi Shukarev, Ine Ilsbroux, Cynthia Robinson, Pontiano Kaleebu
Publicado en: Global Health Action, Edición 13/1, 2020, Página(s) 1829829, ISSN 1654-9716
Editor: Co-Action Publishing
DOI: 10.1080/16549716.2020.1829829

Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach

Autores: Anton Camacho, Rosalind M Eggo, Sebastian Funk, Conall H Watson, Adam J Kucharski, W John Edmunds
Publicado en: BMJ Open, Edición 5/12, 2015, Página(s) e009346, ISSN 2044-6055
Editor: BMJ Publishing Group
DOI: 10.1136/bmjopen-2015-009346

Duration of Ebola virus RNA persistence in semen of survivors: population-level estimates and projections

Autores: Rosalind M Eggo, Conall H Watson, Anton Camacho, Adam J Kucharski, Sebastian Funk, W John Edmunds
Publicado en: Eurosurveillance, Edición 20/48, 2015, Página(s) Volume 20, 2015, ISSN 1025-496X
Editor: Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI: 10.2807/1560-7917.ES.2015.20.48.30083

Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease

Autores: Adam J. Kucharski, Rosalind M. Eggo, Conall H. Watson, Anton Camacho, Sebastian Funk, W. John Edmunds
Publicado en: Emerging Infectious Diseases, Edición 22/1, 2016, Página(s) 105-108, ISSN 1080-6040
Editor: US National Center for Infectious Diseases
DOI: 10.3201/eid2201.151410

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

Autores: Georgi Shukarev, Benoit Callendret, Kerstin Luhn, Macaya Douoguih
Publicado en: Human Vaccines & Immunotherapeutics, Edición 13/2, 2017, Página(s) 266-270, ISSN 2164-5515
Editor: Landes Bioscience
DOI: 10.1080/21645515.2017.1264755

Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

Autores: Daouda Sissoko, Sophie Duraffour, Romy Kerber, Jacques Seraphin Kolie, Abdoul Habib Beavogui, Alseny-Modet Camara, Géraldine Colin, Toni Rieger, Lisa Oestereich, Bernadett Pályi, Stephanie Wurr, Jeremie Guedj, Thi Huyen Tram Nguyen, Rosalind M Eggo, Conall H Watson, W John Edmunds, Joseph Akoi Bore, Fara Raymond Koundouno, Mar Cabeza-Cabrerizo, Lisa L Carter, Liana Eleni Kafetzopoulou, Eeva Kuis
Publicado en: The Lancet Global Health, Edición 5/1, 2017, Página(s) e80-e88, ISSN 2214-109X
Editor: Elsevier BV
DOI: 10.1016/S2214-109X(16)30243-1

Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone

Autores: Luisa Enria, Shelley Lees, Elizabeth Smout, Thomas Mooney, Angus F. Tengbeh, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones, Heidi Larson
Publicado en: BMC Public Health, Edición 16/1, 2016, ISSN 1471-2458
Editor: BioMed Central
DOI: 10.1186/s12889-016-3799-x

Real-time forecasting of infectious disease dynamics with a stochastic semi-mechanistic model

Autores: Sebastian Funk, Anton Camacho, Adam J. Kucharski, Rosalind M. Eggo, W. John Edmunds
Publicado en: Epidemics, Edición 22, 2018, Página(s) 56-61, ISSN 1755-4365
Editor: Elsevier BV
DOI: 10.1016/j.epidem.2016.11.003

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

Autores: Iain D. Milligan, Malick M. Gibani, Richard Sewell, Elizabeth A. Clutterbuck, Danielle Campbell, Emma Plested, Elizabeth Nuthall, Merryn Voysey, Laura Silva-Reyes, M. Juliana McElrath, Stephen C. De Rosa, Nicole Frahm, Kristen W. Cohen, Georgi Shukarev, Nicola Orzabal, Wilbert van Duijnhoven, Carla Truyers, Nora Bachmayer, Daniel Splinter, Nathaly Samy, Maria Grazia Pau, Hanneke Schuitemaker, Kers
Publicado en: JAMA, Edición 315/15, 2016, Página(s) 1610, ISSN 0098-7484
Editor: American Medical Association
DOI: 10.1001/jama.2016.4218

Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges

Autores: An Vandebosch, Robin Mogg, Nele Goeyvaerts, Carla Truyers, Brian Greenwood, Debby Watson-Jones, Guillermo Herrera-Taracena, Wim Parys, Tony Vangeneugden
Publicado en: Clinical Trials: Journal of the Society for Clinical Trials, Edición 13/1, 2016, Página(s) 57-65, ISSN 1740-7745
Editor: SAGE Publications
DOI: 10.1177/1740774515621059

Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone

Autores: A. Camacho, R.M. Eggo, N. Goeyvaerts, A. Vandebosch, R. Mogg, S. Funk, A.J. Kucharski, C.H. Watson, T. Vangeneugden, W.J. Edmunds
Publicado en: Vaccine, Edición 35/4, 2017, Página(s) 544-551, ISSN 0264-410X
Editor: Elsevier BV
DOI: 10.1016/j.vaccine.2016.12.019

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year

Autores: Rebecca L. Winslow, Iain D. Milligan, Merryn Voysey, Kerstin Luhn, Georgi Shukarev, Macaya Douoguih, Matthew D. Snape
Publicado en: JAMA, Edición 317/10, 2017, Página(s) 1075, ISSN 0098-7484
Editor: American Medical Association
DOI: 10.1001/jama.2016.20644

“We are the heroes because we are ready to die for this country”: Participants' decision-making and grounded ethics in an Ebola vaccine clinical trial

Autores: Angus Fayia Tengbeh, Luisa Enria, Elizabeth Smout, Thomas Mooney, Mike Callaghan, David Ishola, Bailah Leigh, Deborah Watson-Jones, Brian Greenwood, Heidi Larson, Shelley Lees
Publicado en: Social Science & Medicine, Edición 203, 2018, Página(s) 35-42, ISSN 0277-9536
Editor: Pergamon Press Ltd.
DOI: 10.1016/j.socscimed.2018.03.008

Citizens, dependents, sons of the soil: Defining political subjectivities through encounters with biomedicine during the Ebola epidemic in Sierra Leone

Autores: Luisa Enria, Shelley Lees
Publicado en: Medicine Anthropology Theory | An open-access journal in the anthropology of health, illness, and medicine, Edición 5/4, 2018, ISSN 2405-691X
Editor: Medicine Anthropology Theory
DOI: 10.17157/mat.5.4.512

Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine

Autores: Martinus A.H. Capelle, Lara Babich, J.P. Els van Deventer-Troost, Doris Salerno, Kelly Krijgsman, Ulrike Dirmeier, Britt Raaby, Janik Adriaansen
Publicado en: European Journal of Pharmaceutics and Biopharmaceutics, Edición 129, 2018, Página(s) 215-221, ISSN 0939-6411
Editor: Elsevier BV
DOI: 10.1016/j.ejpb.2018.06.001

EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country

Autores: Thomas Mooney, Elizabeth Smout, Bailah Leigh, Brian Greenwood, Luisa Enria, David Ishola, Daniela Manno, Mohamed Samai, Macaya Douoguih, Deborah Watson-Jones
Publicado en: Clinical Trials, Edición 15/5, 2018, Página(s) 436-443, ISSN 1740-7745
Editor: SAGE Publications
DOI: 10.1177/1740774518780678

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation

Autores: Chloé Pasin, Irene Balelli, Thierry Van Effelterre, Viki Bockstal, Laura Solforosi, Mélanie Prague, Macaya Douoguih, Rodolphe Thiébaut
Publicado en: Journal of Virology, Edición 93/18, 2019, ISSN 0022-538X
Editor: American Society for Microbiology
DOI: 10.1128/jvi.00579-19

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

Autores: Gaudensia Mutua, Omu Anzala, Kerstin Luhn, Cynthia Robinson, Viki Bockstal, Dickson Anumendem, Macaya Douoguih
Publicado en: The Journal of Infectious Diseases, Edición 220/1, 2019, Página(s) 57-67, ISSN 0022-1899
Editor: University of Chicago Press
DOI: 10.1093/infdis/jiz071

Health care worker vaccination against Ebola: Vaccine acceptance and employment duration in Sierra Leone

Autores: Mario Jendrossek, W. John Edmunds, Hana Rohan, Samuel Clifford, Thomas A. Mooney, Rosalind M. Eggo
Publicado en: Vaccine, Edición 37/8, 2019, Página(s) 1101-1108, ISSN 0264-410X
Editor: Elsevier BV
DOI: 10.1016/j.vaccine.2018.12.060

Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic

Autores: Alexis Robert, W John Edmunds, Conall H Watson, Ana Maria Henao-Restrepo, Pierre-Stéphane Gsell, Elizabeth Williamson, Ira M Longini, Keïta Sakoba, Adam J Kucharski, Alhassane Touré, Sévérine Danmadji Nadlaou, Boubacar Diallo, Mamamdou Saidou Barry, Thierno Oumar Fofana, Louceny Camara, Ibrahima Lansana Kaba, Lansana Sylla, Mohamed Lamine Diaby, Ousmane Soumah, Abdourahime Diallo, Amadou Niar
Publicado en: American Journal of Epidemiology, Edición 188/7, 2019, Página(s) 1319-1327, ISSN 0002-9262
Editor: Oxford University Press
DOI: 10.1093/aje/kwz090

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

Autores: Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, George Praygod, Georgi Shukarev, Daniela Manno, Saidi Kapiga, Heiner Grosskurth, Samuel Kalluvya, Viki Bockstal, Dickson Anumendem, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih, Deborah Watson-Jones
Publicado en: The Journal of Infectious Diseases, Edición 220/1, 2019, Página(s) 46-56, ISSN 0022-1899
Editor: University of Chicago Press
DOI: 10.1093/infdis/jiz070

Control of Ebola virus disease outbreaks: Comparison of health care worker-targeted and community vaccination strategies

Autores: Alexis Robert, Anton Camacho, W. John Edmunds, Marc Baguelin, Jean-Jacques Muyembe Tamfum, Alicia Rosello, Sakoba Kéïta, Rosalind M. Eggo
Publicado en: Epidemics, Edición 27, 2019, Página(s) 106-114, ISSN 1755-4365
Editor: Elsevier BV
DOI: 10.1016/j.epidem.2019.03.001

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.

Autores: Ramon Roozendaal, Jenny Hendriks, Thierry van Effelterre, Bart Spiessens, Liesbeth Dekking, Laura Solforosi, Dominika Czapska-Casey, Viki Bockstal, Jeroen Stoop, Daniel Splinter, Sarah Janssen, Ben van Baelen, Nadia Verbruggen, Jan Serroyen, Eline Dekeyster, Ariane Volkmann, Yvonne Wollmann, Ricardo Carrion, Luis D. Giavedoni, Cynthia Robinson, Maarten Leyssen, Macaya Douoguih, Kerstin Luhn, Maria
Publicado en: npj Vaccines, Edición 5/112, 2020, ISSN 2059-0105
Editor: Nature
DOI: 10.1038/s41541-020-00261-9

Parameter estimation in nonlinear mixed effect models based on ordinary differential equations: An optimal control approach

Autores: Clairon, Quentin; Pasin, Chloé; Balelli, Irene; Thiébaut, Rodolphe; Prague, Mélanie
Publicado en: 2021, Edición 1, 2021
Editor: HAL
DOI: 10.13140/rg.2.2.18016.81920

Derechos de propiedad intelectual

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: 15 767631
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: 15 767631
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: 15 767631
Fecha: 2015-09-03
Solicitante(s): JANSSEN VACCINES & PREVENTION BV

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT /US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT /US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT /US15/48388
Fecha: 2015-09-03
Solicitante(s): JANSSEN VACCINES & PREVENTION BV

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT /US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT /US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT /US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT /US15/48357
Fecha: 2015-09-03
Solicitante(s): JANSSEN VACCINES & PREVENTION BV

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT /US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT /US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT /US15/48357
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES

Número de solicitud/publicación: PCT US15/48388
Fecha: 2015-09-03

METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

Número de solicitud/publicación: PCT US15/48357
Fecha: 2015-09-03

Buscando datos de OpenAIRE...

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854

Resultado final

Publicaciones

Derechos de propiedad intelectual

Compartir esta página

Descargar